Back to today’s briefing

Story perspectives

Helicore Biopharma Secures $65M for Obesity Treatment Trials

1/28/2025

50 9

Summary

Story summary

Helicore Biopharma has secured an impressive $65 million in Series A funding to propel its groundbreaking monoclonal antibody, HCR-188, aimed at combating obesity. Set to enter first-in-human trials in 2025, this innovative treatment directly targets glucose-dependent insulinotropic peptide (GIP), promising to revolutionize weight loss and improve cardiometabolic health.

1 of 1

Story summary

Helicore Biopharma has secured an impressive $65 million in Series A funding to propel its groundbreaking monoclonal antibody, HCR-188, aimed at combating obesity. Set to enter first-in-human trials in 2025, this innovative treatment directly targets glucose-dependent insulinotropic peptide (GIP), promising to revolutionize weight loss and improve cardiometabolic health.